4.6 Review

A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy

期刊

SHOCK
卷 55, 期 6, 页码 700-716

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SHK.0000000000001680

关键词

Coagulation; coagulopathy; COVID-19; DVT; pulmonary embolism; thromboembolism; thrombosis

资金

  1. National Institute of Aging and Robert and Arlene Kogod Center for Aging, Mayo Clinic [T32 AG049672]
  2. National Heart, Lung, and Blood Institute [R38HL150086]
  3. National Institute of General Medical Sciences [R01 GM 126086-03]
  4. National Center for Research Resources (NCRR) [1UL1 RR024150]
  5. National Center forA dvancing Translational Sciences [UL1 TR000135]
  6. Trans-Agency Consortium for Trauma-Induced Coagulopathy [UM1 HL120877-06]

向作者/读者索取更多资源

COVID-19 is associated with significant coagulopathy, leading to increased rates of venous and arterial thromboembolic events. Inflammatory response in COVID-19 is linked to coagulopathy, posing challenges for diagnosis, prevention, and treatment of thrombotic complications. Endothelial injury and augmented innate immune response play a role in the development of thrombosis in COVID-19.
There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a significant coagulopathy, a phenomenon termed COVID-19 associated coagulopathy. COVID-19 has been associated with increased rates of both venous and arterial thromboembolic events, a source of significant morbidity and mortality in this disease. Further evidence suggests a link between the inflammatory response and coagulopathy associated with COVID-19. This presents a unique set of challenges for diagnosis, prevention, and treatment of thrombotic complications. In this review, we summarize and discuss the current literature on laboratory coagulation disruptions associated with COVID-19 and the clinical effects of thromboembolic events including pulmonary embolism, deep vein thrombosis, peripheral arterial thrombosis, and acute ischemic stroke in COVID-19. Endothelial injury and augmented innate immune response are implicated in the development of diffuse macro- and microvascular thrombosis in COVID-19. The pathophysiology of COVID-19 associated coagulopathy is an important determinant of appropriate treatment and monitoring of these complications. We highlight the importance of diagnosis and management of dysregulated coagulation in COVID-19 to improve outcomes in COVID-19 patients with thromboembolic complications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据